Combination treatment with HBIg and LAM reduced HBV recurrence following liver transplantation, compared with HBIg or LAM alone, and reduced mortality compared with HBIg alone.
Combination treatment with HBIg and LAM reduced HBV recurrence following liver transplantation, compared with HBIg or LAM alone, and reduced mortality compared with HBIg alone.
“…We retrieved the 3 papers 11–13 on 2 randomized clinical studies. The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 .…”
Section: Resultsmentioning
confidence: 99%
“…We retrieved the 3 papers 11–13 on 2 randomized clinical studies. The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 . In Lee KW 2001, 11 58 liver transplant patients due to HBV infection were allocated randomly into HBIg group ( n = 30) or combination group ( n = 28).…”
Section: Resultsmentioning
confidence: 99%
“…The 2 studies were coded as Lee KW 2001, 11 Park SJ 2002 12 . In Lee KW 2001, 11 58 liver transplant patients due to HBV infection were allocated randomly into HBIg group ( n = 30) or combination group ( n = 28). Only 43 patients (19 patients of HBIg group and 24 patients of combination group) who survived more than 90 days were included in analysis.…”
Section: Resultsmentioning
confidence: 99%
“…The 2 randomized clinical studies 11,12 were described as randomized, but none had mentioned adequate generation of allocation sequence. None of the 2 trials were labeled as double or single blind or described follow‐up and withdrawals/drop‐outs in detail.…”
Long-term HBIg prophylaxis or lamivudine prophylaxis can reduce the risk for hepatitis B virus recurrence. Long-term high-dose HBIg combined with lamivudine can further reduce HBV recurrence to less than 10%.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.